Novo Nordisk's Confidence Paradox: Raised Guidance Meets Deepening Skepticism
Published on 08/14/2026 at 07:42 | Redaktion boerse-global.de
There is a peculiar disconnect playing out in Copenhagen these days. Novo Nordisk delivered second-quarter numbers that beat expectations, lifted its full-year outlook, and watched its oral weight-loss pill cross five million prescriptions — yet the shares remain stuck in a rut, roughly 26 percent below January's 52-week high of 54.86 euros. The stock closed Thursday at 40.45 euros, leaving it down 8.1 percent for the year and hovering just beneath its 50-day moving average of 41.29 euros.
The tension is not lost on the analyst community, which appears almost evenly split on what to make of the Danish pharma giant. Berenberg cut its rating from "Buy" to "Hold" on August 12, trimming the Copenhagen price target from 325 to 305 Danish kroner, while BMO Capital's Evan Seigerman raised his target to 47 US dollars the same day — yet held the stock at "Market Perform." Two houses, two data points, two nearly opposite conclusions delivered within hours of each other. That divergence captures the market's broader indecision about a company whose operational engine is humming but whose strategic narrative is fraying.
The Numbers Tell One Story
The operational picture is genuinely solid. Adjusted revenue rose 7 percent on a currency-neutral basis in the second quarter, reaching 78.5 billion Danish kroner, while adjusted operating profit climbed 11 percent to 33.4 billion kroner — comfortably ahead of the 28.74 billion kroner analysts had penciled in. Management responded by raising guidance, now projecting adjusted revenue growth of between 0 and minus 6 percent on a currency-neutral basis for 2026, with operating profit tracking a similar range.
The standout performer is the oral version of Wegovy. The pill generated 3.22 billion kroner in quarterly sales and has now surpassed five million prescriptions since its January launch, with more than 265,000 weekly scripts written by mid-July. That is no longer a side project; it is a genuine second pillar alongside the injectable franchise. The company also controls roughly 90 percent of the oral GLP-1 segment, a dominant position that CEO Mike Doustdar argues will matter as the competitive landscape evolves. He told media on Thursday that the obesity market will accommodate multiple winners rather than a winner-take-all duel.
The Doubts Tell Another
Yet the skepticism runs deeper than any single quarter can fix. Berenberg's downgrade rationale points directly at Eli Lilly's expanding footprint across both oral and injectable weight-loss markets, arguing the valuation multiple has little room left to expand. Notably, the house actually raised its 2026 revenue forecast by 2.9 percent to 296.18 billion kroner — a nod to the Wegovy pill's momentum — while cutting its 2028 estimate by 2.3 percent on reduced expectations for CagriSema. That combination is telling: the current business is working, but faith in the next growth wave is eroding.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The CagriSema question is central. Novo Nordisk recently completed the Phase 3b REDEFINE 9 study, which showed placebo-adjusted weight loss with lower maintenance doses and a safety profile consistent with earlier trials. The clinical substance appears intact. The concern is competitive timing: Eli Lilly confirmed on August 7 its schedule for FDA submission of its next-generation product, raising the stakes for how quickly CagriSema can establish itself in the market.
Then there is the Ziltivekimab setback. The Phase 3 ZEUS study, read out in late July, missed its primary endpoint — the drug lowered inflammatory markers as expected but failed to meaningfully reduce major cardiovascular events versus placebo, with a hazard ratio around 0.99. Novo Nordisk insists this does not change the communicated 2026 profit guidance, but it has flagged a non-cash impairment charge of 6.3 billion kroner for the third quarter. The broader implication is uncomfortable: the company's attempt to diversify beyond metabolic medicine into cardiovascular inflammation has stalled, narrowing the growth story back to the very territory where Lilly is attacking most aggressively.
Defensive Moves and Technical Signals
Management is not sitting idle. The expanded partnership with Amazon Web Services, announced in August, is designed to accelerate drug discovery through agentic AI, with the company citing measurable gains such as faster turnaround times in clinical documentation. On the legal front, a Dutch court issued an injunction in August barring a provider of compounded semaglutide nasal sprays from further sales, with patent protection in the Netherlands running through March 2031.
The buyback program continues as well: roughly 27.9 million B-shares have been repurchased since February at an average price of 279.01 kroner, within the framework of the 15-billion-kroner program.
Technically, the stock looks neither broken nor healed. The RSI sits at 44.8, and the shares trade just below their 200-day average — a picture of neutrality bordering on mild weakness. Thirty-day volatility of 39 percent suggests the market itself has not settled on a verdict.
What Comes Next
The near-term catalysts are concrete. The EU launch of the Wegovy 7.2 mg single-dose pen, approved by the EMA in July and slated for the second half of the year, could provide fresh momentum. Beyond that, the first prescription data for CagriSema as it becomes more widely available will be the real test — the point at which the market can judge whether Novo Nordisk's next act can hold its ground against Lilly's coming generation.
For now, the company finds itself in an unusual position: delivering better-than-expected results, raising guidance, and still having to prove itself quarter after quarter. The operational engine is intact, but the confidence premium that once came with it has been spent.
Ad
Novo Nordisk Stock: New Analysis - 14 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
